X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs TORRENT PHARMA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA TORRENT PHARMA AUROBINDO PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 14.8 37.0 40.1% View Chart
P/BV x 3.8 5.8 66.5% View Chart
Dividend Yield % 0.4 0.9 43.1%  

Financials

 AUROBINDO PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
TORRENT PHARMA
Mar-17
AUROBINDO PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs8951,768 50.6%   
Low Rs6221,186 52.5%   
Sales per share (Unadj.) Rs254.6346.1 73.6%  
Earnings per share (Unadj.) Rs39.355.2 71.2%  
Cash flow per share (Unadj.) Rs46.673.3 63.5%  
Dividends per share (Unadj.) Rs2.5014.00 17.9%  
Dividend yield (eoy) %0.30.9 34.8%  
Book value per share (Unadj.) Rs160.0257.1 62.2%  
Shares outstanding (eoy) m585.88169.22 346.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.3 69.8%   
Avg P/E ratio x19.326.8 72.1%  
P/CF ratio (eoy) x16.320.1 80.8%  
Price / Book Value ratio x4.75.7 82.5%  
Dividend payout %6.425.4 25.1%   
Avg Mkt Cap Rs m444,390249,887 177.8%   
No. of employees `00014.011.8 118.7%   
Total wages/salary Rs m17,6789,934 177.9%   
Avg. sales/employee Rs Th10,667.84,971.5 214.6%   
Avg. wages/employee Rs Th1,264.3843.2 149.9%   
Avg. net profit/employee Rs Th1,645.8792.4 207.7%   
INCOME DATA
Net Sales Rs m149,15758,569 254.7%  
Other income Rs m1,1592,233 51.9%   
Total revenues Rs m150,31660,802 247.2%   
Gross profit Rs m34,34313,773 249.4%  
Depreciation Rs m4,2763,069 139.3%   
Interest Rs m6672,056 32.5%   
Profit before tax Rs m30,55810,881 280.8%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,5971,545 491.7%   
Profit after tax Rs m23,0129,336 246.5%  
Gross profit margin %23.023.5 97.9%  
Effective tax rate %24.914.2 175.1%   
Net profit margin %15.415.9 96.8%  
BALANCE SHEET DATA
Current assets Rs m92,06253,841 171.0%   
Current liabilities Rs m66,22331,612 209.5%   
Net working cap to sales %17.338.0 45.6%  
Current ratio x1.41.7 81.6%  
Inventory Days Days10697 109.1%  
Debtors Days Days6884 80.8%  
Net fixed assets Rs m62,91942,079 149.5%   
Share capital Rs m586846 69.2%   
"Free" reserves Rs m93,13342,655 218.3%   
Net worth Rs m93,71943,501 215.4%   
Long term debt Rs m1,81422,408 8.1%   
Total assets Rs m162,494101,250 160.5%  
Interest coverage x46.86.3 743.7%   
Debt to equity ratio x00.5 3.8%  
Sales to assets ratio x0.90.6 158.7%   
Return on assets %14.611.3 129.5%  
Return on equity %24.621.5 114.4%  
Return on capital %32.719.6 166.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m75,83820,066 377.9%   
Fx outflow Rs m30,2245,304 569.8%   
Net fx Rs m45,61314,762 309.0%   
CASH FLOW
From Operations Rs m32,78610,127 323.7%  
From Investments Rs m-17,870-7,869 227.1%  
From Financial Activity Rs m-19,153-1,918 998.6%  
Net Cashflow Rs m-4,239212 -2,004.1%  

Share Holding

Indian Promoters % 54.1 71.5 75.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 7.0 113.2%  
FIIs % 27.7 12.6 219.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 8.8 115.9%  
Shareholders   69,601 26,511 262.5%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   GLENMARK PHARMA  J.B.CHEMICALS  DR. REDDYS LAB  DIVIS LABORATORIES  FULFORD INDIA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Trade War Fears; Widening of Trade Deficit and Top Stocks in Action Today(Pre-Open)

Indian share markets trimmed their day's losses and ended flat on Friday amid weakness in their Asian peers, that wobbled on Friday as investors braced for US tariffs against China.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 15, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS